QT Imaging Holdings Inc

QT Imaging Holdings Inc(QTI)股票分析

$2.030

-0.039 (-1.93%)收盘时

Loading chart…
最高
2.150
开盘
2.070
成交量加权均价
2.06
成交量
28.49K
市值
—
最低
2.010
成交额
58.78K
企业价值/息税折旧摊销前利润(TTM)
-1.66

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.

AI 分析 of QT Imaging Holdings Inc (QTI)

买入

QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.

估值指标

QT Imaging Holdings Inc(QTI)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-0.96
当前EV/EBITDA
-1.66
高估
2.00
低估
-3.93

预期市销率

合理
5 年均值 P/S
0.18
当前P/S
0.53
高估
0.54
低估
-0.19

事件时间线

2026-10-07 (ET)

09:00:00

QT Imaging Partners with NXC Imaging for National Purchasing Agreement

2026-09-17 (ET)

09:00:00

QT Imaging Appoints Mark Winkler as Chief Medical Officer

2026-08-12 (ET)

16:30:00

QT Imaging Reports Q2 Revenue of $7.4M, Below Estimates

2026-08-04 (ET)

09:00:00

QT Imaging Appoints New VPs to Advance U.S. Sales Strategy

2026-07-29 (ET)

09:00:00

QT Imaging Appoints Julia Albright as Chief Science Officer

资讯

QTI 常见问题 —— 由 Alphio AI 解答

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易